TARGETIBDBYPLA2

A Novel Drug Targeting Strategy for the Treatment of Inflammatory Bowel Disease: A Molecular Biopharmaceutical Approach

 Partecipanti

Mappa

+-

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'A molecular approach will be applied to mechanistically target drugs - by exploiting phospholipase A2 (PLA2) - to diseased tissues in inflammatory bowel disease (IBD). PLA2 hydrolyses the sn-2 fatty acyl bond of phospholipids (PL), liberating a fatty-acid and a lysophospholipid. We have shown that by substituting the sn-2 fatty-acid of the PL with a drug, PLA2 may be exploited as a prodrug activating enzyme, liberating the free drug from the PL-complex. Further, PLA2 affinity to the prodrug and the intestinal permeability of the whole prodrug can be manipulated by the conjugate design. PLA2 expression/activity has been shown to be significantly elevated in tissues of patients with IBD - both Crohn’s disease and ulcerative colitis. We posit that since the activation of the PL-drug conjugate is PLA2 mediated, increased PLA2 levels in the diseased tissue will lead to increased free drug in the actual diseased tissues, accompanied by decreased drug levels in non-diseased areas, resulting in extended therapeutic index and improved drug therapy. The proposed research will mechanistically facilitate specific targeting of 5-aminosalicylic acid (5ASA) for proof-of-concept. However, targeting of other drugs will be enabled by the core approach developed in this research. The specific aims are: 1) to design and synthesize a library of PL-5ASA conjugates with different linkers between the PL and the drug moiety; 2) to evaluate the PLA2-mediated activation and the intestinal permeability of the prodrugs (enabling the design/synthesis of optimal conjugates), thereby to identify the most promising prodrugs; and 3) to develop an IBD rat model, to quantify PLA2 expression/activity in diseased vs. control animals, and to evaluate the leading PL-5ASA conjugates for in-vivo drug targeting, pharmacokinetics and pharmacodynamics vis-à-vis other 5ASA products. The findings will significantly improve drug therapy in IBD patients, enabling higher efficacy and lower toxicity profiles.'